1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 02 NOVEMBER 2015

Cancer Drug News 02 NOVEMBER 2015

  • November 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - World's First Oncolytic Viral Therapy Adds Contender To Melanoma Market
Industry Brief - Igenica/MedImmune Enter Oncology Research Collaboration
Industry Brief - Celgene's Vidaza Approved In Europe For Elderly Patients With AML
Industry Brief - Stemline's SL-401 Gains EU Orphan Designation For BPDCN
Industry Brief - Keytruda Superior To Chemotherapy In PD-L1-Expressing NSCLC
Industry Brief - Telesta/Ipsen Sign Ex-US Licensing Deal For MCNA In High-Risk NMIBC
Industry Brief - Keytruda Gains FDA Breakthrough Therapy Designation For Advanced CRC
Industry Brief - FDA Approves Yervoy As Adjuvant Treatment For Stage III Melanoma
Industry Brief - Lenvima Launched In Switzerland
Industry Brief - Kite To License AIS' TIP Technology To Advance CAR/TCR Product Candidates
Industry Brief - MacroGenics Regains Global Rights To Enoblituzumab
Industry Brief - ProBioGen and Bio Farma Enter Trastuzumab Agreement
Industry Brief - Orexo Settles Fentanyl Litigation With Actavis
Industry Trend Analysis - Metabolic And Oncology Areas To Support Growth Prospects

Table Of Contents

Cancer Drug News 02 NOVEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.